Emmaus appoints George Sekulich to board and Willis Lee as Chairman

Emmaus Life Sciences, Inc.

George Sekulich appointed to fill board vacancy created by Yutaka Niihara's resignation on Sept 25, 2023.
Sekulich also serves as Co-President and Chief Commercial Officer; previously SVP and CIO since July 2019.
Willis Lee, Co-President and COO, appointed as Chairman of the Board of Directors on October 2, 2023.
No family relationships or related-party transactions with Sekulich were disclosed.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Willis Lee

Chairman of the Board of Directors

EMMA · Emmaus Life Sciences, Inc.

Effective: 2023-10-02
Filed: October 4, 2023, 7:59 PM ET

Also on October 2, 2023, the Board of Directors appointed Willis Lee, the Co-President and Chief Operating Officer, to serve as Chairman of the Board of Directors.

Departed

Yutaka Niihara

Director

EMMA · Emmaus Life Sciences, Inc.

Effective: 2023-09-25
Successor: George Sekulich
Filed: October 4, 2023, 7:59 PM ET

Yutaka Niihara, M.D., M.P.H., the former Chairman and Chief Executive Officer, resigned as a director effective September 25, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Willis Lee was appointed as Chairman of the Board of Directors at Emmaus Life Sciences, Inc..

Action: appointed
Role: Chairman of the Board of Directors

Exact text from the filing

Also on October 2, 2023, the Board of Directors appointed Willis Lee, the Co-President and Chief Operating Officer, to serve as Chairman of the Board of Directors.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Yutaka Niihara resigned as Director at Emmaus Life Sciences, Inc..

Action: resigned
Role: Director

Exact text from the filing

Yutaka Niihara, M.D., M.P.H., the former Chairman and Chief Executive Officer, resigned as a director effective September 25, 2023.

View on SEC.gov

Emmaus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001013762-23-001586

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.